Ten Year Experience of Epidemiological Trends and Clinical Pattern of Vulvar Tumor

Diptajit Paul, Abhishek Soni, Sumit S Chatterjee, Abhirup Chanda, Vivek Kaushal, Ashok Chauhan

Department of Radiation Oncology, Pt BD Sharma PGIMS Rohtak, Haryana, India. College of Medicine & JNM Hospital, Kalyani, WBUHS, India.

Abstract

Objectives: Vulvar tumor is a relatively uncommon female genito-urinary tumor, occurs mainly in post-menopausal females. Incidence and patterns of vulvar tumor differ from nation to nation, depending upon multiple factors. The aim of this study was to evaluate epidemiological patterns and clinical profile of vulvar tumor in our institution retrospectively. Methods: This is a retrospective study done in a regional cancer centre of India over 10-years period. Data of all vulvar tumor patients, regarding demographic profile and tumor characteristics were collected from record section and reviewed. These data were analysed to get an idea about clinic-epidemiological trends of vulvar malignancy. Results: Total 47-patients with biopsy proven vulvar malignancy were found. Mean age at presentation was 63.4 years. Majority of the patients belonged to rural origin, were post-menopausal and multiparous. Most of them had pruritus as typical presenting symptoms. Histopathologically, squamous cell carcinoma constituted the major bulk. Labia was the commonest site of presentation. Bilateralism was found in one-third among them, inguinal lymphadenopathy and extensive disease were found in five and four patients, respectively. Conclusions: The hallmark about the present article is that it was conducted in the only referral cancer institute of this state. Limited studies from different region of India have published local patients’ data on vulvar tumor. A nationwide collaboration in this regard will help to understand the exact burden of this relatively rare malignancy, epidemiological trends and risk factors as well as an idea about how to manage these patients.

Keywords: Epidemiology- labia- postmenopausal- squamous cell carcinoma- vulvar tumor

Introduction

Vulvar tumor, a relatively uncommon female genito-urinary tumor, contributes around 2000 new cases every year in India [1]. It constitutes approximately 4% of all gynaecological malignancies and less than 1% of all female cancers [2,3]. Old age, addiction of smoking, chronic dermatological condition like lichen and long-time infection with human papilloma virus (HPV) are the major risk factors associated with vulvar malignancy [4-6]. Majority of vulvar tumor are squamous cell carcinoma (SCC); rare varieties include melanoma, Paget’s disease, basal cell carcinoma & lymphoma [4,7]. Diagnosis is confirmed by detailed history and physical examination, vulvar biopsy and clinical imaging. Staging is done according to International Federation of Gynaecology and Obstetrics [FIGO] guideline [2,8]. Incidence and patterns of vulvar tumor differ from nation to nation, depending upon multiple factors [9]. Retrospective studies on vulvar malignancy from Western and Northeast part of India depicted epidemiological trends in those areas [10,11]. A few cancer institutes of Northern India have also reported their patients’ data [2,3]. The objective of this analysis was to evaluate epidemiological trends and clinical profile of vulvar tumor in our institution retrospectively.

Materials and Methods

This is a single institution-based retrospective study
done in a regional cancer centre over a period of 10-years from January 2010 to December 2019. Permission from Institutional Review board was taken. Data regarding socio-demographic profile and tumor characteristics of all patients, having either fine needle aspiration cytology (FNAC) or biopsy proven vulvar malignancy, encountered in that stipulated time were collected from record section and reviewed. Informed consent was taken from the live patients as far as possible. All data thus gathered was analyzed using software (Microsoft Excel and Statistical Package for Social Sciences) to get a visualization about epidemiological trends and clinical pattern of vulvar malignancy in this part of nation and also compared with the global statistics.

**Results**

During the entire period, a total 10548-female patients having histologically confirmed malignancy were registered, of which 47-patients had biopsy proven vulvar malignancy. These constituted approximately 0.45% of total malignancy diagnosed in women.

The age of the patients ranged from 30 to 90 years with mean age at presentation being 63.4 years. Greater part of the cases (49%) was seen in seventh and eighth decade of life (Figure 1). Majority of the patients belonged to rural origin, rural to urban ratio being 2.9:1. Among all, around 78% patients (n=37) were post-menopausal at the time of diagnosis and only 7-patients (15%) were nulliparous. Overall, only 3-patients had a history of tobacco intake in the form of hookah smoking, others were free of addiction as per records.

At initial visit, 33-patients (70%) had a fair general condition with Karnofsky performance status (KPS) >70; only 3-patients had KPS <30 i.e. poor condition and the rest had average health status (KPS 30-70). Bulk of the patients had pruritus as typical presenting symptoms (61%) followed by ulceration (26%). Discharge from local site and pain were often associated with primary complaints. The duration of symptoms ranged from 2 to 14 months with a mean of eight months. Histopathologically, squamous cell carcinoma (SCC) constituted the major bulk (91.5%; n=43), most of them were either well- or moderately differentiated in grading. 4-cases of rare neoplasms were also observed; 1-case each of non-hodgkin lymphoma and vulvar melanoma and two cases of Paget’s disease. Verrucous carcinoma, the rare but indolent variant of SCC, was seen in 3-patients (Table 1).

Labia (either majora, or minora or both) was the commonest site of presentation (76%; n=36). Bilateral vulva involvement was seen in 15-patients among these. These was ensued by inguinal lymphadenopathy and extensive multiple site involvement in five and four patients, respectively. 4-patients had disease in clitoris, while the patients diagnosed with NHL had localized, solid, non-tender, undistinguishable swelling. Surprisingly, none of the patient in our analysis had distant metastasis.

Staging was done in all patients of vulvar SCC according to FIGO 2018 guideline, while the lymphoma and melanoma patient was staged as per Ann Arbor and Breslow staging system, respectively. Distribution of all SCC cases as per FIGO stage of disease was illustrated in Figure 2.

**Discussion**

Our institute is a regional cancer centre and the only tertiary cancer centre serving all the cancer patients of this state over last three to four decades. Vulvar cancer is comparatively an infrequent malignancy with only 45240 cases per year globally [12]. Due to rarity of its occurrence, large scale prospective study would not be possible. Patient and tumor characteristics along with different treatment modalities and their impact over outcome in vulvar malignancy were mainly extrapolated from retrospective reviews. In recent years, a few articles globally have reported demographic and clinico-pathological profiles of vulvar tumor patients by retrospective analysis (Table 2).
Table 2. Various Case Series/retrospective Studies Published on Vulvar Tumors

<table>
<thead>
<tr>
<th>Author</th>
<th>Year</th>
<th>Time period</th>
<th>Number of patients</th>
<th>Age</th>
<th>Post-menopausal status (%)</th>
<th>Multiparous (% of patients)</th>
<th>Histology</th>
</tr>
</thead>
<tbody>
<tr>
<td>Schuurman et al [13]</td>
<td>2013</td>
<td>22 years</td>
<td>5680</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>SCC-4614 Melanoma-341 Others-725</td>
</tr>
<tr>
<td>Buttmann-Schweiger et al [14]</td>
<td>2015</td>
<td>13 years</td>
<td>13125</td>
<td>71-73 years (median)</td>
<td>-</td>
<td>-</td>
<td>Melanoma-4</td>
</tr>
<tr>
<td>Singh et al [3]</td>
<td>2016</td>
<td>10 years</td>
<td>41</td>
<td>52 years (mean)</td>
<td>68.30</td>
<td>87.80</td>
<td>SCC - 40 Non SCC – 1</td>
</tr>
<tr>
<td>Kehila et al [15]</td>
<td>2017</td>
<td>17 years</td>
<td>76</td>
<td>65.4 years (mean)</td>
<td>86.80</td>
<td>82.90</td>
<td>SCC-72 Melanoma-4</td>
</tr>
<tr>
<td>Lakhwani et al [16]</td>
<td>2019</td>
<td>2.5 years</td>
<td>5</td>
<td>58 years (mean)</td>
<td>100</td>
<td>80</td>
<td>SCC-5</td>
</tr>
<tr>
<td>Mousavi et al [17]</td>
<td>2019</td>
<td>20 years</td>
<td>106</td>
<td>59.2 years (mean)</td>
<td>80.20</td>
<td>92.50</td>
<td>SCC-79 Melanoma-3 Others-26</td>
</tr>
<tr>
<td>Tanaka et al [18]</td>
<td>2019</td>
<td>35 years</td>
<td>815</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>SCC-389 Melanoma-28 Others-</td>
</tr>
</tbody>
</table>

[3, 11, 13-18]. However, number of similar article from our country is limited. Incidence, demography, risk factors and tumor properties vary over geographical and cultural differences, it is worthwhile to document the same in the patients addressed by our hospital.

In the present study, the incidence of vulvar malignancy among all women malignancy is 0.45% which is nearly similar to study done by Chhabra et al in Western India [11]. However, Prevalence of vulvar cancer varies grossly over different parts of world. Southern Africa and Europe comprise a high burden of this malignancy, while the disease is infrequent in Gulf countries [9]. This might be due to prevalence of contributing infections like human-papilloma virus (HPV), behaviours factors like smoking and sexual habits in these population apart from geographical variations only.

Mean and median age of the patients analysed here were 63.4 and 66 years, respectively. These correlated very well with the conclusion of earlier published studies carried out in Northeast India as well in Western world [10, 19]. Age specific prevalence analysis, according to decade of life, revealed maximum cases (12 out of 47) in eighth decade of life i.e. between 70 to 79 years of age and minimum cases (4/47) in 4th decade (between 30 to 39 years) of life; which consolidated the outcome of previous study by Ouh et al [20]. No cases in our analysis was below 30 years of age. In a recently published global population based study, the researchers also concluded that incidence of vulvar cancer declined in women below 60-years of age, particularly for Indian inhabitants [9]. However, in comparison to the European literature, where the median age of vulvar tumor patients is around 71-73 years, our patients in the present review had comparatively younger age [21, 22]. Another study conducted in a Southern African country, where prevalence of vulvar cancer is comparatively more, median age of vulvar cancer patients was 42. This is due to higher prevalence of human immune virus (HIV) epidemic in that country and around 90% of that patient’s cohort were having prior HIV infection [23]. Anyhow, such variation in data demarcates the need of such study around different parts of world.

In these review, 76% of the total patients had disease in labia, and approximately two third had bilateral disease. These findings are very much in line with the global values [24]. However, local nodal involvement was seen in less patients (11% only) than that found in other studies [22, 25]. More than 90% of the vulvar malignancy in our institution revealed squamous cell carcinoma (SCC), which is consistent with other articles published over different parts of world [4, 7, 26]. Histological grading of all SCC tumors matched closely with National Cancer Institute (NCI) data [19]. Rare neoplasms were also found and addressed as per existing literature [27-29]. Bulk of the patients (nearly 70%) in our study were locally advanced that is in stage II and III; while around 15% cases were in stage I and IV. These values are similar with another Indian study by Nandwani et al, but does not match with the analysis by Lai et al [10, 30]. These may be due to deficiency of health awareness and lack of routine health check-up in our country. However, it is also satisfying to mention not a single patient was having stage IVB disease i.e. distant organ involvement.

The hallmark about the present article is that it was conducted in the regional cancer centre, where collaboration between all related department i.e. gynecology, surgical-oncology, dermatology, and obviously radiation oncology, occurred. Limitation includes the retrospective nature of the analysis, and obviously, lack of immune-histochemical analysis in vulvar tumor. Another important fact not to miss, this analysis conducted on patients of vulvar tumor registered on our regional cancer centre only. A few patients visited outside our hospital,
either to private clinicians or opted for traditional herbal medicine, cannot be counted and included in this review. Those will add more patients in our study cohort and help us to draw more clear cut idea about these less occurring tumor.

In conclusion, our study concludes that with a mean age of 63.4 years, vulvar cancer remains a health burden for older, especially for post-menopausal females. HPV and HIV status of these patients was not available in records and hence comments on their contribution in occurrence of vulvar tumor cannot be possible. Limited studies from different region of India have published local patients’ data on vulvar tumor. A nationwide collaboration in this regard will help to understand the exact burden of this relatively rare malignancy, epidemiological trends and risk factors as well as an idea about how to manage these patients.

References

status of patients with vulvar squamous cell carcinoma in northern Italy. Scientific Reports. 2021 03 11;11(1):5661. https://doi.org/10.1038/s41598-021-85030-x


